HBIO vs UDR · rev $22.7M vs P/E 26, rev $1.71B
Harvard Bioscience Inc (HBIO) versus UDR Inc (UDR) — a side-by-side from cached financials, not a winner call.
Harvard Bioscience Inc (HBIO) is a medical instruments & supplies company listed on US.
UDR Inc (UDR) is a reit - residential company listed on NYSE.
Latest reported HBIO revenue for 2026-06-30 was $22.7M. Net income was -$2.9M. Revenue was up 9.5% from 2026-03-31 to 2026-06-30. HBIO currently screens at market cap $20.3M.
Latest reported UDR revenue for 2025-12-31 was $1.71B. Net income was $377.7M. Revenue was up 2.4% from 2024-12-31 to 2025-12-31. UDR currently screens at market cap $13.95B and trailing P/E 25.6.
HBIO currently screens at market cap $20.3M. UDR currently screens at market cap $13.95B and trailing P/E 25.6.
Not investment advice. Open the HBIO and UDR stock pages for the full models.
Not investment advice.